# Trade Mark Journal No.2025/039 26 September 2025

## WO0000001874696 (1,5,42)

Office of origin: United States of America

Date of International Registration:6 November 2024
Date of designation in the UK: 6 November 2024

The mark consists of a stylized Ampersand symbol.

International priority date claimed: 7 May 2024 (United States of America) (98537469)

Class 1
  Biological and chemical agents for scientific use other than for medical use, namely, biological and chemical preparations for scientific purposes being addressable and programmable protein-based therapeutics.
Class 5
  Biological therapeutics, namely, addressable and programmable protein-based therapeutics, including multi-specific polypeptide-based therapeutics, namely, therapeutic pharmaceuticals for the treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders; pharmaceutical preparations, namely, addressable and programmable protein-based therapeutics, for treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders.
Class 42
  Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services.

Ampersand Biomedicines, Inc.

Representative: Christina Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA